Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05231122 |
Title | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer |
Recruitment | Recruiting |
Gender | female |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Roswell Park Cancer Institute |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |